Related references
Note: Only part of the references are listed.Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis
Charlotte Gran et al.
ACTA HAEMATOLOGICA (2020)
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
Vaishali Sanchorawala et al.
BLOOD (2020)
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
Christoph R. Kimmich et al.
BLOOD (2020)
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis
Oliver C. Cohen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
Suzanne Lentzsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Two types of systemic amyloidosis in a single patient
Riccardo Papa et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis
Oliver C. Cohen et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini et al.
BLOOD (2020)
Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?
Pui-Lun Yip et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Venetoclax for the treatment of translocation (11;14) AL amyloidosis
M. Hasib Sidiqi et al.
BLOOD CANCER JOURNAL (2020)
Doxycycline decreases amyloidogenic light chain-induced autophagy in isolated primary cardiac myocytes
Maria Valero-Munoz et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2020)
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
Anita D'Souza et al.
ECLINICALMEDICINE (2020)
Organ responses with daratumumab therapy in previously treated AL amyloidosis
Alfred Chung et al.
BLOOD ADVANCES (2020)
Daratumumab proves safe and highly effective in AL amyloidosis
Jack Khouri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
Jithma P. Abeykoon et al.
LEUKEMIA (2019)
Two types of amyloidosis presenting in a single patient: a case series
M. Hasib Sidiqi et al.
BLOOD CANCER JOURNAL (2019)
Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function
M. Hasib Sidiqi et al.
BONE MARROW TRANSPLANTATION (2019)
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)
Guido Ghilardi et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy
Richa Manwani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
Richa Manwani et al.
BLOOD (2019)
Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis
M. Hasib Sidiqi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis
Mohammed A. Aljama et al.
BLOOD ADVANCES (2019)
One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis
Camille V. Edwards et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
Diagnosis and management of neuropathies associated with plasma cell dyscrasias
Evan Rosenbaum et al.
HEMATOLOGICAL ONCOLOGY (2018)
Transthyretin familial amyloid polyneuropathy: an update
Violaine Plante-Bordeneuve
JOURNAL OF NEUROLOGY (2018)
Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)
Pooja Phull et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)
High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease
Felipe Batalini et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone
Nelson Leung et al.
HAEMATOLOGICA (2018)
Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era
Arnt V. Kristen et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2018)
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone
Nelson Leung et al.
HAEMATOLOGICA (2018)
Venetoclax for the treatment of multiple myeloma
Iuliana Vaxman et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Light Chain (AL) Amyloidosis: The Journey to Diagnosis
Kristen L. McCausland et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
E. Muchtar et al.
LEUKEMIA (2017)
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
Ute Hegenbart et al.
HAEMATOLOGICA (2017)
Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response
Martha Grogan et al.
HEART (2017)
Heart transplantation in cardiac amyloidosis
Matthew Sousa et al.
HEART FAILURE REVIEWS (2017)
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience
Taxiarchis V. Kourelis et al.
MAYO CLINIC PROCEEDINGS (2017)
Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis
Hallie I. Geller et al.
MAYO CLINIC PROCEEDINGS (2017)
Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy
Michael S. Scully et al.
MILITARY MEDICINE (2017)
MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis
Martin Winter et al.
PROTEOMICS (2017)
Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy
Amit R. Patel et al.
JACC-CARDIOVASCULAR IMAGING (2017)
Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
A. D. Wechalekar et al.
BLOOD CANCER JOURNAL (2017)
Importance of FISH genetics in light chain amyloidosis
Morie A. Gertz et al.
ONCOTARGET (2017)
Liver transplantation in transthyretin amyloidosis: Characteristics and management related to kidney disease
Ana Rocha et al.
TRANSPLANTATION REVIEWS (2017)
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
Ute Hegenbart et al.
HAEMATOLOGICA (2017)
Transthyretin Cardiac Amyloidosis
Anit K. Mankad et al.
CURRENT CARDIOLOGY REPORTS (2017)
Cardiac Amyloidosis as a Potential Confounder in Heart Failure With Preserved Ejection Fraction Trials
Erik B. Schelbert et al.
JACC-HEART FAILURE (2017)
Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis
Jin-Young Huh et al.
BLOOD RESEARCH (2017)
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays
Giovanni Palladini et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2017)
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Gregory P. Kaufman et al.
BLOOD (2017)
Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis
Jonathan S. Wall et al.
PHARMACEUTICAL PATENT ANALYST (2017)
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala et al.
BLOOD (2017)
Stem cell transplantation for immunoglobulin light chain amyloidosis
Taimur Sher et al.
CURRENT PROBLEMS IN CANCER (2017)
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Eli Muchtar et al.
BLOOD (2017)
Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis
Camille V. Edwards et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Luciano J. Costa et al.
BLOOD ADVANCES (2017)
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation
Nelson Leung et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
Vaishali Sanchorawala et al.
BLOOD (2016)
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis
Taimur Sher et al.
BLOOD (2016)
Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis
Morie A. Gertz et al.
CANCER (2016)
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore et al.
CIRCULATION (2016)
Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy
Philippe Kerschen et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2016)
Primarily isolated hepatic involvement of amyloidosis A case report and overview
Lei Ye et al.
MEDICINE (2016)
A More Accurate Approach to Amyloid Detection and Subtyping: Combining in situ Congo Red Staining and Immunohistochemistry
Thomas Menter et al.
PATHOBIOLOGY (2016)
Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis
Ajai Chari et al.
BLOOD (2016)
Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Adam D. Cohen et al.
BLOOD (2016)
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
Isabelle Lousada et al.
ADVANCES IN THERAPY (2015)
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
Maria T. Cibeira et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis
Federico Cacciapuoti
JOURNAL OF ECHOCARDIOGRAPHY (2015)
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial
Xianghua Huang et al.
BMC MEDICINE (2014)
FAP Neuropathy and Emerging Treatments
David Adams et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2014)
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
Giovanni Palladini et al.
HAEMATOLOGICA (2014)
Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis
D. E. Meyers et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
M. A. Gertz et al.
BONE MARROW TRANSPLANTATION (2013)
Systemic Amyloidosis in England: an epidemiological study
Jennifer H. Pinney et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Relationship between monoclonal gammopathy and cardiac amyloid type
Joseph J. Maleszewski et al.
CARDIOVASCULAR PATHOLOGY (2013)
Paraneoplastic neuropathies
Francesc Graus et al.
CURRENT OPINION IN NEUROLOGY (2013)
Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis
Taxiarchis V. Kourelis et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
H. Landau et al.
LEUKEMIA (2013)
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
Laura Obici et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2012)
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue
Francesca Brambilla et al.
BLOOD (2012)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
Joseph R. Mikhael et al.
BLOOD (2012)
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
Efstathios Kastritis et al.
BLOOD (2012)
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Angela Dispenzieri et al.
BLOOD (2012)
Ten-Year Survival After Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis
Stefan Cordes et al.
CANCER (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Amyloid detection and typing: summary of current practice and recommendations of the consensus group
M. M. Picken et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2011)
Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
Jennifer Ellis Ward et al.
BLOOD (2011)
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis
Umit Tapan et al.
BLOOD (2010)
Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models
Isabel Cardoso et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence
A. Bernard Collins et al.
CARDIOVASCULAR PATHOLOGY (2009)
Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study
Maarit Tanskanen et al.
ANNALS OF MEDICINE (2008)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Angela Dispenzieri et al.
BLOOD (2007)
Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model
I. Cardoso et al.
FASEB JOURNAL (2006)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
A Dispenzieri et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies
A Solomon et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
Share Paper
